Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
5(29%)
Results Posted
80%(4 trials)
Terminated
3(18%)

Phase Distribution

Ph phase_1
8
47%
Ph phase_2
5
29%
Ph not_applicable
3
18%

Phase Distribution

8

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
8(50.0%)
Phase 2Efficacy & side effects
5(31.3%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

5

trials recruiting

Total Trials

17

all time

Status Distribution
Active(5)
Completed(5)
Terminated(4)
Other(3)

Detailed Status

Completed5
Recruiting4
Terminated3
unknown3
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
5
Success Rate
62.5%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (50.0%)
Phase 25 (31.3%)
N/A3 (18.8%)

Trials by Status

terminated318%
recruiting424%
unknown318%
withdrawn16%
completed529%
active_not_recruiting16%

Recent Activity

5 active trials
Showing 5 of 17
recruitingnot_applicable

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

NCT06682117
terminatedphase_1

DC Vaccine in Colorectal Cancer

NCT03730948
active_not_recruitingphase_2

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

NCT01686334
recruiting

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

NCT06043232
terminatedphase_1

DC Vaccination in CML

NCT02543749
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT06682117Not Applicable

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

Recruiting
NCT03730948Phase 1

DC Vaccine in Colorectal Cancer

Terminated
NCT01686334Phase 2

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

Active Not Recruiting
NCT06043232

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

Recruiting
NCT02543749Phase 1

DC Vaccination in CML

Terminated
NCT02334735Phase 2

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Completed
NCT05000801Not Applicable

Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

Recruiting
NCT04999943Phase 1

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Recruiting
NCT04567069Phase 1

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

Unknown
NCT02151448Phase 1

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Completed
NCT01876212Phase 2

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Completed
NCT02956551Phase 1

Personalized DC Vaccine for Lung Cancer

Unknown
NCT01671592Phase 1

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

Completed
NCT00913913Phase 2

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Terminated
NCT00978913Phase 1

Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma

Completed
NCT00935558Phase 2

Dendritic Cell Based Therapy for Breast Cancer Patients

Withdrawn
NCT00327496Not Applicable

Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells

Unknown

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17